trending Market Intelligence /marketintelligence/en/news-insights/trending/qdbxrciwcciw1wqypimzla2 content esgSubNav
In This List

ASCO conference: CytomX therapy shows anti-tumor activity in phase 1/2 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: CytomX therapy shows anti-tumor activity in phase 1/2 study

CytomX Therapeutics Inc.'s CX-072 was well tolerated as a standalone treatment and showed anti-tumor activity in a phase 1/2 study of patients with advanced solid tumors that cannot be removed through surgery.

The study, named PROCLAIM-072, is evaluating the drug as a monotherapy and in combination with Bristol-Myers Squibb Co.'s Yervoy or Genentech Inc.'s Zelboraf.

CX-072 targets programmed death ligand 1, or PD-L1, a protein found on the surface of cancer cells that helps them evade body's cancer-killing immune cells.

Results from the study showed that CX-072, both as a monotherapy and in combination with Yervoy, was well-tolerated with the majority of treatment-related side effects being mild or moderate.

Out of the patients who received just CX-072, three saw a reduction in the size of their tumors and eight patients' disease did not increase or decrease in severity. Decreased target lesions were observed in eight patients in six of the subset of patients who received a higher dose of the drug.

Among the 12 patients who received CX-072 along with Yervoy, three saw a decrease in the size of their tumors and the disease remained stable in 8% of patients.

CytomX did not disclose data for the group receiving CX-072 in combination with Zelboraf.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.